Revolution Medicines opened lower at $188.38, compared with its previous close of $190.27. In the last trading session, the stock traded between $187.28 and $191.51. It showed a downward intraday trend.
return calculator
Time Period
An investment of $100 made 5 years ago in Revolution Medicines is now worth
$ 640.13
giving a profit of
$ 540.13 (540.13%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 24 Analysts
Buy
95.83%
Hold
4.17%
Sell
0%
Markets Today
Today's Change
$-1.88 (-0.99%)
Day High
$191.51
Day Low
$187.28
Day Open
$188.38
Prev Close
$190.27
Volume
2,80,518
1W Return
0.39%
1M Return
-7.81%
3M Return
4.15%
6M Return
34.04%
1Y Return
224.70%
Fundamentals
Market Cap ($ Mn)
40,379
PE Ratio
-
PB Ratio
17.09
PEG Ratio
-
ROE
-59.94%
ROCE
-54.86%
EPS (TTM)
$-3.01
Investment Returns
1 Week
0.39%
1 Month
-7.81%
3 Months
4.15%
6 Months
34.04%
9 Months
91.84%
Financials
Quarterly
All values in $ Mn
0.0
Dec 24
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
Updates
22Oct
Revolution Medicines Q3FY26 Results: Earnings release set for Nov 4
Revolution Medicines will report Q3FY26 financial results on November 4, 2026. Management webcast scheduled for 4:30 pm ET on the same day. Company focuses on RAS-addicted cancers using RAS(ON) inhibitor platform.
8 days ago
21Oct
TD Cowen reiterates Buy on Revolution Medicines with $250 target
TD Cowen reiterated a Buy rating on Revolution Medicines. Analyst Tyler Van Buren announced a $250 price target.
9 days ago
19Oct
Truist maintains Buy on Revolution Medicines, lifts price target to $241
Truist Securities analyst Gregory Renza maintained a Buy rating on Revolution Medicines. The price target was raised from $240 to $241. The rating action reflects a slight upward revision in valuation expectations.
11 days ago
16Oct
William Blair initiates coverage on Revolution Medicines with Outperform rating
William Blair analyst Alethia Young initiated coverage on Revolution Medicines. The stock was assigned an Outperform rating. The action signals a positive initial assessment by the research firm.
14 days ago
15Oct
Revolution Medicines gets EU CHMP positive opinion for Rasonque
CHMP recommends marketing authorization for Rasonque in EU. Phase 3 trial showed 60% reduction in risk of death vs chemo. Median overall survival improved to 13.2 months from 6.7 months. First broad RAS-targeted option for metastatic pancreatic cancer.
15 days ago
15Oct
Needham reiterates Buy on Revolution Medicines, keeps $275 price target
Needham analyst Ami Fadia reiterated a Buy rating on Revolution Medicines. The firm maintained its price target at $275 per share. This follows RBC Capital's recent Outperform rating with a $260 target. Analysts maintain positive fundamental views on the company.
